The efficiency of systemic-to-pulmonary shunts in older children with hypoplastic pulmonary arteries
Related Experiment Video
Updated: Jan 25, 2026

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
Published on: February 11, 2017
Han Zhang1, Xiangming Fan1, Junwu Su1
1Pediatric Cardiac Center, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China.
Insights
Systemic-pulmonary shunts (SPSs) improve oxygen saturation and pulmonary artery growth in older children with hypoplastic pulmonary arteries. Younger age and forward pulmonary artery flow positively impact artery development post-surgery.
Area of Science:
- Pediatric Cardiology
- Congenital Heart Surgery
- Vascular Biology
Background:
- Hypoplastic pulmonary arteries present a significant challenge in managing cyanotic congenital heart disease in older children.
- Systemic-to-pulmonary shunts (SPSs) are a palliative strategy, but their impact on pulmonary artery development requires further investigation.
Purpose of the Study:
- To evaluate the effectiveness of SPSs in older children with hypoplastic pulmonary arteries.
- To identify factors influencing pulmonary artery growth after palliative shunting.
Main Methods:
- Retrospective analysis of 86 children (age > 3 years) who underwent SPSs.
- Collection of perioperative data and postoperative pulmonary artery diameters.
- Analysis of factors affecting pulmonary artery growth post-shunt.
Main Results:
- Postoperative oxygen saturation (SpO2) improved significantly (71.7% to 85.2%).
- The McGoon ratio increased from 0.96 to 1.30, indicating pulmonary artery growth (P < 0.05).
- Younger age (<5 years) and forward pulmonary artery flow were key positive factors for artery growth (P < 0.05).
Conclusions:
- SPSs benefit older children with cyanotic heart disease, enhancing oxygenation and pulmonary artery development.
- Early intervention (age < 5 years) and adequate antegrade pulmonary artery flow are crucial for optimal postoperative pulmonary artery growth.
Background:
To investigate the effects of systemic-to-pulmonary shunts (SPSs) in older children with hypoplastic pulmonary arteries and the factors affecting the development of the pulmonary arteries.
Methods:
Eighty-six children (older than 3 years) who received SPSs were retrospectively analyzed. The perioperative parameters, the postoperative diameter of the pulmonary artery were collected, and the factors influencing the growth of the pulmonary arteries after an initial palliative shunt operation were analyzed.
Results:
Two patients died postoperatively (2.33%), and the pulse oxygen saturation (SpO2 ) increased from 71.70 ± 6.75% preoperatively to 85.20 ± 11.07% at discharge. During the follow-up period of 56 (10-99) months, 37 patients (43.02%) underwent subsequent procedures, and in the remaining patients, the McGoon ratio was increased from 0.96 ± 0.48 at the surgery to 1.30 ± 0.31 at the final assessment (P < 0.05). Univariate analysis indicated that age younger than 5 years old (P < 0.05), pulmonary artery forward flow (P < 0.05) and a diagnosis of tetralogy of Fallot (P < 0.05) played positive roles in the growth of the pulmonary artery after surgery, while children with a McGoon ratio less than 0.6 showed poor development of the pulmonary arteries (P < 0.05). Multivariate analysis showed that age younger than 5 years old (P < 0.05) and pulmonary artery forward flow (P < 0.05) were positive effectors on the growth of the pulmonary artery.
Conclusions:
Older children with cyanotic congenital heart disease benefited from a systemic-pulmonary shunt and showed increased postoperative oxygen saturation and development of the pulmonary arteries. Age younger than 5 years and pulmonary artery antegrade flow were the positive factors influencing the growth of the pulmonary arteries postoperatively.
Related Concept Videos
Overview of Systemic and Pulmonary Circulation
The oxygenated blood is sent...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

